Do peptides help with inflammation and inflammatory bowel disease?
4 peptides are graded for inflammation and inflammatory bowel disease on this page. The strongest grade is human RCT evidence, for thymosin alpha-1. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.
What is the standard of care for inflammation and inflammatory bowel disease?
Depends on the condition: NSAIDs, corticosteroids, immunomodulators, and biologics for inflammatory bowel disease and autoimmune disease under specialist care.
Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.
Which peptides have been studied for inflammation and inflammatory bowel disease?
Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.
| Peptide | Evidence for this use | Note |
|---|---|---|
| Thymosin alpha-1 | Evidence: Human RCT evidence | Approved in several countries (not the US) for hepatitis B and as an immune adjuvant; trials in sepsis. [1] |
| VIP (vasoactive intestinal peptide) | Evidence: Human observational evidence | Uncontrolled human studies of inhaled VIP in sarcoidosis. The record's human_rct grade comes from intravenous aviptadil trials in COVID-19 respiratory failure, a different route and indication; not approved. [1] |
| KPV | Evidence: Animal-only evidence | Alpha-MSH fragment; reduced colitis in mouse models; PCAC recommended for 503A bulks list in July 2026. [1] |
| BPC-157 | Evidence: Animal-only evidence | Protection against NSAID and colitis models in rodents. [1] [2] |
Head-to-head comparisons
Cost and access
Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.
Frequently asked questions
Which peptide has the strongest evidence for inflammation and inflammatory bowel disease?
Thymosin alpha-1 has the strongest evidence among the peptides graded here, at human RCT evidence. Approved in several countries (not the US) for hepatitis B and as an immune adjuvant; trials in sepsis. [1]
Is any peptide FDA approved for inflammation and inflammatory bowel disease?
No. None of the peptides graded for inflammation and inflammatory bowel disease is an FDA approved drug, so any use is outside an approved label and depends on the compounding and research status shown on each peptide page. [3]
Has any peptide been tested in a randomized trial for inflammation and inflammatory bowel disease?
Yes, for Thymosin alpha-1. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1]
From the blog
- BPC-157 for gut health: the animal evidence and the missing human trials
BPC-157 healed ulcers, colitis, fistulas, and short bowel in rats. No human gut trial has published results. What the GI studies found, what is missing, and what has human evidence.
- BPC-157 human studies: every published report and registered clinical trial
Every published BPC-157 human report, with sample size and limits, plus every registered clinical trial on ClinicalTrials.gov. About 30 people, no control groups, and no randomized results yet.
- Klow vs Glow peptide: what KPV adds and what is known
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
Sources
- [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [2]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Curr Pharm Des 2011)PubMed 21548867, 2011
- [3]Drugs@FDA: FDA-approved drugs databaseFDA